Capricor's Duchenne treatment fails to get FDA approval, shares sink
AI Image

Capricor's Duchenne treatment fails to get FDA approval, shares sink

Reuters • • business

Key Points:

  • The FDA rejected Capricor's application for deramiocel, a therapy aimed at preserving upper-limb function in Duchenne muscular dystrophy patients, citing serious data integrity issues in a key clinical trial.
  • The agency identified unauthorized changes to the analysis plan, violations of blinding rules, and other protocol breaches that compromised the reliability of the study data, concluding the treatment did not meet its primary endpoints.
  • Capricor's CEO Linda Marban strongly criticized the FDA's decision, asserting that the company stands behind its independently validated data and warning that the rejection harms the Duchenne community.
  • The regulatory setback significantly impacts Capricor's lead experimental asset and commercial outlook, following a prior advisory committee vote that questioned the treatment's effectiveness in Duchenne-related heart disease.
  • Duchenne muscular dystrophy is a fatal genetic disorder causing progressive muscle weakness, primarily in boys, leading to loss of mobility, heart complications, and premature death.

Trending Business

Trending Technology

Trending Health